



Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 17/05/2022

Ref: 21-22 584

Dear Sir or Madam,

Freedom of Information request

Firstly, please accept our sincere apologies for the delay in providing you with a response. Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 17/02/2022. Please see responses to your requests below.

1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Bevacizumab
- Brigatinib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy or combination with Carboplatin/Cisplatin
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine
- Lorlatinib
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Pemetrexed with Carboplatin/Cisplatin
- Tepotinib

- Vinorelbine with Carboplatin/Cisplatin
- Any other active systemic anti-cancer therapy (SACT)
- Palliative care only

The Trust is only able to provide information in relation to drug dispensing, we do not record diagnoses on our clinical systems so therefore we are unable to link the type of drug to diagnosis.

Therefore, to extract this information, we would have to search through a significant amount of patient records. It is estimated that to attempt to retrieve all the information you require would take a considerable amount of retrieval time, which would exceed 18 hours. This would exceed the appropriate limit for dealing with a Freedom of Information Request, in terms of costs and therefore Section 12(1) of the Freedom of Information Act 2000 applies.

2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Durvalumab
- Gemcitabine
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab (Keytruda) with Chemotherapy
- Other active systemic anti-cancer therapy (SACT)
- Palliative care only

Please see exemption in question 1.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team